Biotech Values

[jq1234]

So, in your opinion, this is not incremental change in cancer? Even for melanoma, this is nowhere near the most promising candidate, check Plexxikon (a private company) whose BRAF inhibitor PLX4032 with KNOWN mechanism of action showed 80% response rate. Even with 80% ORR it is still incremental improvement because it doesn't make metastatic melanoma a chronical disesase.